ESMO Breast 2022 | Treatment for HER2+ metastatic breast cancer

Rupert Bartsch, MD, Medical University of Vienna, Vienna, Austria, talks on new agents in the field of HER2-positive metastatic breast cancer, including the antibody-drug conjugate (ADC) trastuzumab deruxtecan and the tyrosine kinase inhibitor (TKI) tucatinib. First-line standard of care for HER2-positive metastatic breast cancer is currently taxane plus trastuzumab pertuzumab. Prof. Bartsch additionally discusses the treatment of patients depending on whether they have active brain metastasis or not. Those with active brain metastasis and no indication for immediate local therapy would be treated with the triple combination of tucatinib, trastuzumab and capecitabine in the second-line setting. Trastuzumab deruxtecan is the standard second-line treatment for patients without brain metastasis or stable brain metastasis. This interview took place at the European Society for Medical Oncology (ESMO) Breast Cancer 2022 congress in Berlin, Germany.